Effectiveness of the BBIBP-Corv vaccine in health personnel from the Andean Trapeze of Peru, February - June 2021. Retrospective cohort study

Vaccine preventable diseases

Peru has the highest mortality from COVID-19 globally, and the start of vaccination in February-2021 have given a lot of hope in the midst of the rise of the 2nd wave of the pandemic, with health personnel being the first to receive the vaccine.
Objective: Determine the effectiveness of the BBIBP-Corv vaccine in health personnel in the less socially favored Region, the Andean Trapeze-Peru.
Retrospective cohort study in health personnel (11,505 unvaccinated/44,201 vaccinated with 2 doses) older than 18 years old between February-June 2021 in Apurimac, Ayacucho, Cusco, Huancavelica and Puno Regions. Secondary information from the MOH was used, including: vaccination records, laboratory results, hospital information and death registration. Interdose period was 21 days, with follow-up for 14 weeks, until detection of the events of infection, hospitalization or death. For the vaccinated cohort, the subject was considered infected if it had a positive PCR/Antigenic test result 14 days after the 2nd dose. Vaccine effectiveness (VE) and 95%CI were calculated using STATA v.16. Additionally, VE was estimated in people 60 years old or older (VE60+).
2,067 SARS-CoV2 cases were confirmed by PCR/antigen test (1,367 received 2 doses and 700 were unvaccinated). To prevent infection, the VE=28.4%,95%CI[21.5-34.7];VE60+=27.7%[20.8-34.1]. There were 86 hospitalized for COVID-19 (27 vaccinated and 59 unvaccinated). To prevent hospitalization, VE=82.5%[71.9- 89.3];VE60+=84.8%[75.8-90.4]. 19 deaths from COVID-19 were reported (1 vaccinated and 18 unvaccinated). To prevent deaths, VE=97.9%[86.9-99.9];VE60+=98.6%[89.2-99.8] were found. The national effectiveness was VE=36.8%[34.7-38.7], VE=80.2%[76.1-83.6] and VE=94.6%[92.0-96.5] for the three events studied, respectively. The lowest vaccine efficacies to prevent infection VE=24.5%;VE60+=26.5%, and to prevent deaths VE=88.6%;VE60+=90.3% were in Puno; and to prevent hospitalization VE=82.5%;VE60+=77.6% in Cusco. Values were adjusted by Poisson regression.
The effectiveness of BBIBP-Corv vaccine to prevent infection (VE=28.4%,95%CI[21.5-34.7]) in the Andean Trapeze is significantly lower than the national average. No remarcable differences were found for hospitalization and death.

Please email us if you have any corrections.

If this abstract has been converted into a full article, please email us the link. We would love to help promote your work.